Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tci GeneROCO:6879 67 EV-to-EBITDA is 2.79 as of Sep. 07, 2026, which is 79% below its 10-year median of 13.03. GuruFocus rates ROCO:6879 with a GF Score™ of 67/100 and a GF Value™ of NT$35.51 (Fairly Valued). The stock has 7 warning signs investors should review. Among 399 Biotechnology companies, Tci Gene ranks better than 74.19% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tci Gene's enterprise value is NT$176.5 Mil.
Tci Gene's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$63.3 Mil. Therefore, Tci Gene's EV-to-EBITDA for today is 2.79.
The historical rank and industry rank for Tci Gene's EV-to-EBITDA or its related term are showing as below:
ROCO:6879'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.64 Med: 13.03 Max: 57.16
Current: 2.79
During the past 7 years, the highest EV-to-EBITDA of Tci Gene was 57.16. The lowest was 1.64. And the median was 13.03.
ROCO:6879's EV-to-EBITDA is ranked better than 74.19% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs ROCO:6879: 2.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tci Gene's share price for today is NT$35.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tci Gene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Tci Gene's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6879 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Tci Gene's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tci Gene's EV-to-EBITDA falls into.
Tci Gene's current Enterprise Value is NT$176.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tci Gene's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$63.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tci Gene (ROCO:6879) has a EV-to-EBITDA of 2.79 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tci Gene. This is 79% below median its historical median of 13.03. Over the past decade, Tci Gene's EV-to-EBITDA has ranged from 1.64 to 57.16. According to the industry distribution chart, Tci Gene ranks #103 out of 399 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Tci Gene's EV-to-EBITDA too high?
Tci Gene's current EV-to-EBITDA of 2.79 is 79% below median its 10-year median of 13.03. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 57.16. The Biotechnology industry median EV-to-EBITDA is 13.70. Tci Gene's value of 2.79 is 79.6% below this industry median. Based on the distribution chart, Tci Gene ranks #103 out of 399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tci Gene has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tci Gene's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tci Gene ranks #103 out of 399 companies for EV-to-EBITDA. This puts Tci Gene in the upper half of its industry. The industry median EV-to-EBITDA is 13.70. Tci Gene's value of 2.79 is 79.6% below this benchmark. Historically, Tci Gene's own EV-to-EBITDA has ranged from 1.64 to 57.16 over the past decade. While the company's 10-year median is 13.03 vs. the industry median of 13.70, Tci Gene has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tci Gene's current EV-to-EBITDA of 2.79 is 79.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tci Gene. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tci Gene's current EV-to-EBITDA is 2.79, which is 79% below median its own 10-year median of 13.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tci Gene stock overvalued right now?
Based on GuruFocus' analysis, Tci Gene (ROCO:6879) is currently considered Fairly Valued. The stock's GF Value™ is NT$35.51, compared to a current price of NT$35.55 — trading 0.1% above its estimated fair value. The current EV-to-EBITDA is 2.79, which is 79% below median its 10-year median of 13.03 and 79.6% below the Biotechnology industry median of 13.70. Tci Gene's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tci Gene (ROCO:6879), the current EV-to-EBITDA is 2.79 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tci Gene (ROCO:6879) Overvalued in 2026?
Based on GuruFocus' analysis, Tci Gene stock appears to be overvalued.
The current stock price of NT$35.55 is trading 0.1% above its estimated GF Value™ of NT$35.51.
GuruFocus considers Tci Gene to be Fairly Valued.
Key valuation signals for ROCO:6879:
EV-to-EBITDA: 2.79 (79% below median its 10-year median of 13.03)
GF Value™: NT$35.51 vs. price of NT$35.55 (0.1% above fair value)
Industry Position: 79.6% below the Biotechnology median (#103 of 399)
No single metric tells the full story. See the ROCO:6879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
67GF Score
Get the complete analysis for ROCO:6879
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6879 has been successfully added to your 
